These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. The integration of molecular diagnostics with therapeutics. Implications for drug development and pathology practice. Ross JS; Ginsburg GS Am J Clin Pathol; 2003 Jan; 119(1):26-36. PubMed ID: 12520694 [TBL] [Abstract][Full Text] [Related]
29. Pharmaceutical industry overview: optimal drug therapy. Blake P Can J Clin Pharmacol; 2001; 8 Suppl A():48A-52A. PubMed ID: 11586380 [TBL] [Abstract][Full Text] [Related]
30. Pharmacogenetics: development issues and solutions for safe and effective medicines. Arnold HP; McHale D Pharmacogenomics; 2006 Mar; 7(2):149-55. PubMed ID: 16515393 [No Abstract] [Full Text] [Related]
31. Proceedings of the plenary sessions of the 19th International Congress of Chemotherapy. Montreal, Canada, July 16-21, 1995. Am J Med; 1995 Dec; 99(6A):1S-92S. PubMed ID: 8585527 [No Abstract] [Full Text] [Related]
32. Should off-label drug use be off-the-table? Rivkees SA J Pediatr Endocrinol Metab; 2007 Feb; 20(2):171-2. PubMed ID: 17396432 [No Abstract] [Full Text] [Related]
33. [Pharmacology and pharmacotherapy in Japan]. Van Zwieten PA Ned Tijdschr Geneeskd; 1990 Mar; 134(11):549-50. PubMed ID: 2320149 [No Abstract] [Full Text] [Related]
34. [What is a real therapeutic advance]. Assist Inferm Ric; 2002; 21(3):152-60. PubMed ID: 12593081 [No Abstract] [Full Text] [Related]
35. The second annual Burrill personalized medicine conference. Razvi ES IDrugs; 2007 Jan; 10(1):26-9. PubMed ID: 17187310 [No Abstract] [Full Text] [Related]
36. Novel technology and the development of pharmacogenetics within the pharmaceutical industry. Gibson N; Jawaid A; March R Pharmacogenomics; 2005 Jun; 6(4):339-56. PubMed ID: 16004553 [TBL] [Abstract][Full Text] [Related]
37. Disease management: partnering for better patient care. Sylvestri MF; Marro EP Med Interface; 1996 Jul; 9(7):100-4. PubMed ID: 10159274 [TBL] [Abstract][Full Text] [Related]
38. Capitated chronic disease management programs: a new market for pharmaceutical companies. Cave DG Benefits Q; 1995; 11(3):6-23. PubMed ID: 10151119 [TBL] [Abstract][Full Text] [Related]
39. Perlegen sciences, inc. Peacock E; Whiteley P Pharmacogenomics; 2005 Jun; 6(4):439-42. PubMed ID: 16004563 [TBL] [Abstract][Full Text] [Related]
40. Disease management. Getting out from under drug companies' shadows. Heimoff S Manag Care; 2000 Mar; 9(3):39-40, 42-3. PubMed ID: 11066212 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]